Title: Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Authors: Kurzeder, Christian ×
Bover, Isabel
Marmé, Frederik
Rau, Joern
Pautier, Patricia
Colombo, Nicoletta
Lorusso, Domenica
Ottevanger, Petronella
Bjurberg, Maria
Marth, Christian
Barretina-Ginesta, Pilar
Vergote, Ignace
Floquet, Anne
Del Campo, Josep M
Mahner, Sven
Bastière-Truchot, Lydie
Martin, Nicolas
Oestergaard, Mikkel Z
Kiermaier, Astrid
Schade-Brittinger, Carmen
Polleis, Sandra
du Bois, Andreas
Gonzalez-Martin, Antonio #
Issue Date: Jul-2016
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:34 issue:21
Article number: JCO660787
Abstract: The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
J Clin Oncol 2016.pdf Accepted 996KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science